Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828269 | 1.00 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL3066347 | 0.87 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL10160183 | 0.86 | SMN1; SMN2 (0.85) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL4582840 | 0.84 | PTPN1 (0.63) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL27608578 | 0.84 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL16594624 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL6961718 | 0.83 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL2081781 | 0.83 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL12862921 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB | |
| SCHEMBL28347032 | 0.83 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2HPGDL3MBTL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-2096105-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor | Laboratorios Almirall, S.A. (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | ALDH1A1 3289/4885SMN1; SMN2 3053/4885HPGD 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.